Phibro Animal Health Corporation (PAHC) Q3 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed picture. Positive elements include increased revenue, EBITDA, and net income guidance, as well as growth in the Animal Health and Mineral Nutrition segments. However, geopolitical volatility, foreign currency losses, and increased interest expenses pose risks. The Q&A section highlighted minimal impact from the Middle East conflict and a conservative guidance approach. Performance Products segment decline and inventory buildup are concerns. Overall, the positive and negative factors balance each other, leading to a neutral stock price prediction.
Key Financial Performance
Net Sales Net sales increased 10% to $383 million year-over-year, driven by strong performance in the Animal Health segment and increased demand across various product categories.
Adjusted EBITDA Adjusted EBITDA increased 11% to $60 million year-over-year, attributed to higher sales and gross profit, partially offset by increased SG&A expenses.
Animal Health Segment Sales Animal Health segment sales grew 13% to $291.2 million year-over-year, driven by demand in North America, growth in nutritional specialties (8%), and vaccines (16%).
Mineral Nutrition Segment Sales Mineral Nutrition segment sales increased 10% to $73.4 million year-over-year, due to higher demand for zinc and trace minerals.
Performance Products Segment Sales Performance Products segment sales decreased 17% to $18.9 million year-over-year, due to lower demand for ingredients used in personal care products.
Adjusted Net Income Adjusted net income increased 19% year-over-year, driven by higher gross profit, partially offset by higher SG&A expenses and interest expenses.
Free Cash Flow Generated $13 million of positive free cash flow for the 12 months ended March 31, 2026, impacted by inventory buildup to meet increasing customer demand.
Operating Cash Flow Generated $66 million of operating cash flow year-over-year, with $53 million invested in capital expenditures.
Gross Leverage Ratio Gross leverage ratio was 3.1x at the end of the quarter, based on $741 million of total debt and $241 million of trailing-twelve-month adjusted EBITDA.
Net Leverage Ratio Net leverage ratio was 2.8x at the end of the quarter, based on $663 million of net debt and $241 million of trailing-twelve-month adjusted EBITDA.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Sustainable Solutions Platform and Verratain: Launched a new sustainable solutions platform and introduced Verratain, Verified Sustainability Solutions, through a partnership with VAXA. This platform aims to address customer needs for supply chain emissions reduction, focusing on scalable and practical solutions for long-term growth.
Brazil Regulatory Changes: Brazil implemented a new regulatory framework removing growth promotion and performance indications for certain antimicrobials, including virginiamycin and bacitracin. Phibro is working with regulators to transition and secure therapeutic registrations for these products.
Financial Performance: Net sales increased by 10% to $383 million, and adjusted EBITDA grew by 11% to $60 million. Animal Health sales rose by 13%, driven by demand for MFAs, nutritional specialties, and vaccines.
Liquidity Enhancement: Upsized revolving credit facility by $125 million through an oversubscribed process, enhancing financial flexibility.
Leadership Transition: Danny Bendheim will assume the CEO role in July 2026, with Jack Bendheim transitioning to Executive Chairman.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Changes in Brazil: Brazil has implemented a new regulatory framework that removes growth promotion and performance indications for certain antimicrobials, including virginiamycin and bacitracin. This could impact sales and margins in the region, as these products had a higher-than-average margin profile. The transition to therapeutic use may create short-term disruptions.
Geopolitical Volatility in the Middle East: Elevated geopolitical volatility in the Middle East is affecting poultry demand, which could impact sales and operational stability in the region.
Foreign Currency Losses: The company experienced $1.9 million in foreign currency losses this quarter, compared to gains in the previous year. This could affect profitability if currency volatility continues.
Interest Rate Exposure: Interest expense increased by $1.1 million due to the expiration of an interest rate swap agreement, which could lead to higher financial costs in the future.
Inventory Build-Up: Inventory levels have increased in advance of tariffs and to meet rising customer demand. This could tie up cash flow and create inefficiencies if demand does not materialize as expected.
Decline in Performance Products Segment: Net sales in the Performance Products segment decreased by 17%, driven by lower demand for ingredients used in personal care products. This decline could impact overall revenue and profitability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Net Sales Guidance: Updated from a range of $1.45 billion-$1.5 billion to $1.46 billion-$1.5 billion for fiscal year 2026, representing a growth range of 13%-16% with a midpoint of approximately 14%.
Adjusted EBITDA Guidance: Updated from a range of $245 million-$255 million to $247 million-$255 million for fiscal year 2026, representing a growth range of 34%-39% with a midpoint of approximately 37%.
Adjusted Net Income Guidance: Updated from a range of $120 million-$127 million to $122 million-$127 million for fiscal year 2026, representing growth of 44%-49% with a midpoint of approximately 47%.
Brazil Virginiamycin Sales Impact: Sales of virginiamycin in Brazil were $26 million in fiscal year 2025. Approval for therapeutic claims is anticipated during the 6-month transition period, with the impact on fiscal year 2027 to be better quantified after final approval. Growth in other areas is expected to offset this headwind.
Inventory Stabilization: Inventory buildup in advance of tariffs and increasing customer demand is expected to stabilize in the coming quarters.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Quarterly Dividend: Consistent with history, a quarterly dividend of $0.12 per share was paid, amounting to $4.9 million in aggregate.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the size of the sustainability market opportunity for Verratain, and how does it compare to products like Experior and Bovaer?
A:The sustainability market based on Scope 3 pledges within the Fortune 500 measures in the tens of billions to hundreds of billions of dollars. Verratain allows companies to achieve their pledges economically, unlike other products. Experior deals with ammonia, which is not a greenhouse gas, and Bovaer is a methane reduction product primarily for the dairy industry. Verratain works across species and is not directly competing with these products.
Q:What is the company's exposure to the Middle East conflict in terms of shipping costs and higher oil prices?
A:The fiscal year 2027 guidance includes potential additional shipping and freight costs as well as potential downsides to the business in the Middle East. The company sells vaccines in the region but has not seen much impact so far. The downside risk is considered small and incorporated into the guidance range.
Q:Why does the fourth implied guidance suggest a notable slowdown, and were there any pull-forward dynamics in the quarter?
A:There were no pull-forward dynamics in Q3. The slowdown is due to stronger comparators between Q3 and Q4 of 2025, with Q3 sales at $348 million and Q4 sales at $379 million. The revenue guidance for the year was conservative due to unknowns related to the Middle East conflict, but the company anticipates being towards the higher end of the guidance range.
Q:Review of Unclear Management Responses
A:None of the questions were avoided or lacked clarity. All responses provided sufficient detail and addressed the questions directly.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Brazil antimicrobial
Brazil approach
Brazil culmination
Brazil framework
CEO Chief
CEO role
Chairman chapter
Conference conference
East portfolio
MAPA agency
MFAs specialty
Officer webcast
Phibro Vet
Regina
Solutions customer
Sustainability Solutions
Verified Sustainability
Verratain Verified
Verratain solution
Vet platform
adoption solution
agency year
analyst investor
market
platform Verratain
process
solution platform
stage
supply
today Phibro
transition
use
virginiamycin bacitracin
PAHC Transcript
Phibro Animal Health Corporation (PAHC) Q3 2026 Earnings Call Transcript
Unknown5-7
The earnings call summary presents a mixed picture. Positive elements include increased revenue, EBITDA, and net income guidance, as well as growth in the Animal Health and Mineral Nutrition segments. However, geopolitical volatility, foreign currency losses, and increased interest expenses pose risks. The Q&A section highlighted minimal impact from the Middle East conflict and a conservative guidance approach. Performance Products segment decline and inventory buildup are concerns. Overall, the positive and negative factors balance each other, leading to a neutral stock price prediction.
Phibro Animal Health Corporation (PAHC) Q2 2026 Earnings Call Transcript
Positive2-5
The earnings call summary and Q&A reveal strong financial performance, optimistic guidance, and strategic initiatives like the Phibro Forward, which are expected to drive growth. Despite some concerns over inventory buildup and unclear management responses on specific details, the overall sentiment is positive due to robust margins, favorable market trends, and promising product launches. The positive reception of Restoris and share gains in key segments further bolster the outlook, suggesting a likely stock price increase in the short term.
Phibro Animal Health Corporation (PAHC) Q1 2026 Earnings Call Transcript
Positive11-6
The earnings call reveals strong financial performance, with notable growth in net sales and adjusted EBITDA, especially in the Animal Health segment. The optimistic guidance and strategic initiatives, such as the Phibro Forward Initiative and Zoetis portfolio contributions, support a positive outlook. Despite some uncertainties in growth sustainability, management's confidence in demand and profitability, along with strategic expansions into companion animals, suggest a favorable market reaction. The decision not to update guidance reflects caution rather than negative sentiment, aligning with a positive stock price outlook.
Phibro Animal Health Corporation (PAHC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Neutral9-9
PAHC Slides
PAHC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
